Two-part Phase 1/2 study of OPK-88006, including an open-label SAD phase in healthy participants and a double-blind, randomized, placebo-controlled MAD phase in participants with presumed MASH, to evaluate safety, PK, and MASH related pharmacodynamic changes compared to placebo.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
SAD - OPK-88006 maximum plasma concentration (Cmax)
Timeframe: 2 hours to 1 week
SAD - OPK-88006 Time to peak (Tmax)
Timeframe: 2 hours to 1 week
SAD - OPK-88006 Elimination half-life (T1/2)
Timeframe: 10 hours to 200 hours
SAD - Frequency of treatment emergent adverse events (TEAE)
Timeframe: Up to 2 weeks
MAD - Frequency of treatment emergent adverse events (TEAE)
Timeframe: Up to 20 weeks
MAD - Change in body weight
Timeframe: Up to 17 weeks
MAD - Change in fasting lipids
Timeframe: Up to 17 weeks
MAD - Change in liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
Timeframe: Up to 17 weeks
MAD - Change in liver stiffness with Vibration-controlled Transient Elastography (VCTE)
Timeframe: Up to 17 weeks
MAD - Change in fibrosis markers measured by Enhanced Liver Fibrosis (ELF) score
Timeframe: Up to 17 weeks
MAD - Change in hepatic fat measured by MRI-PDFF
Timeframe: Up to 17 weeks